Katelyn Daniels, Physician Scientist Instructor at St. Jude Children’s Research Hospital, shared a post on LinkedIn:
“Excited to share our latest publication in The Lancet Haematology reporting the final results of the VENAML trial in children, adolescents, and young adults with relapsed or refractory AML.
I’m grateful for the opportunity to contribute to this work and help bring these results to publication. Thank you to an incredible team of collaborators and to the patients and families who made this study possible.”
Title: Venetoclax in combination with cytarabine with or without idarubicin or azacitidine in children, adolescents, and young adults with relapsed or refractory acute myeloid leukaemia (VENAML): a multicentre, phase 1 expansion study
Authors: Katelyn P Daniels, Stanley B Pounds, Huiyun Wu, Lei Wang, Thomas B Alexander, Amit Budhraja, Joshua Wolf, Tamara Westover, Paul E Mead, Cyrus M Mehr, Soumyasri Das Gupta, Norman J Lacayo, Hiroto Inaba, Matthew Rees, Ching-Hon Pui, Joseph T Opferman, Jeffery M Klco, Jeffrey E Rubnitz, Seth E Karol
Other articles featuring Katelyn Daniels on OncoDaily.
